Home / Guidelines
Guidelines
FDA issues guidance for labelling biologicals and biosimilars
The US Food and Drug Administration (FDA) has issued two new guidance documents that provide recommendations to industry on labelling requirements for biologicals and biosimilars.
FDA issues final guidance on biosimilar user fees
The US Food and Drug Administration (FDA) has issued final guidance on the agency’s Biosimilar User Fee Act (BsUFA) II fee structure finalizing the changes introduced since BsUFA I.
FDA withdraws biosimilar statistical guidance
The US Food and Drug Administration (FDA) announced on 21 June 2018 that it had withdrawn the draft guidance on analytical studies of biosimilars. The agency does, however, plan to issue an amended version that ‘will reflect state-of-the-art techniques in the evaluation of analytical data’ and give sponsors ‘appropriate flexibility’.
FDA issues draft guidance on biosimilar meetings
The US Food and Drug Administration (FDA) has issued new draft guidance that provides recommendations to industry on formal meetings between FDA and sponsors or applicants relating to the development and review of biosimilar or interchangeable biological products.
FDA issues guidance on quality considerations for inhaled drugs
The US Food and Drug Administration (FDA) has issued draft guidance on quality considerations for inhaled drugs.
Global guidelines for biosimilars
Last update: 15 June 2018
The public health arm of the United Nations is World Health Organisation (WHO).
WHO, via its biological standardisation programme, develops guidelines and recommendations on the production and control of biological products and technologies.
FDA issues guidance on good manufacturing practice for APIs
The US Food and Drug Administration (FDA) has finalized revised guidance on good manufacturing practice (GMP) for active pharmaceutical ingredients (APIs).
FDA issues final guidance on bioanalytical method validation
On 21 May 2018, the US Food and Drug Administration issued final guidance on bioanalytical method validation.
TGA proposes changes to biologicals regulations
Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA) announced on 20 April 2018 the release of proposed amendments to its biologicals regulations that are set to take effect on 1 July 2018.
Regulation of biologicals in Colombia
Since the introduction of Decree 1782 Colombia has been moving towards a new regulatory landscape for biologicals (productos bioterapéuticos) and similar biotherapeutic products (productos bioterapéuticos similares) in the country [1].
Generics News Research General
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
Biosimilars News Research General
- Collaboration between regulatory authorities fo...Biosimilars/Research | Posted 26/02/2021
- Biosimilar approvals and launches in the USBiosimilars/General | Posted 26/02/2021
- Biosimilars approved in AustraliaBiosimilars/General | Posted 21/02/2014
- Biosimilar approvals and patent litigation in t...Biosimilars/General | Posted 19/02/2021